×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Loan Against Mutual Fund
Apply Now
Gold Loan
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Vouchers
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Budget 2026
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
PF
Forum
Videos
you are here:
Home
News
Ur Associates
Ur Associates
Pharma cos bag 28% of total US FDA approvals in CY12
National pharma pricing policy 2012 ties up all loose ends
Infra: Govt regains form, debutant player to perform well
Govt formulates plan to strengthen power sector
Recent govt actions will not impact pharma sector
Infra: Promise needs to be delivered; time to reverse
Private participation to underpin infra investment
New pharma pricing policy to be finalized in November
Pharma cos strong performance may continue in Q2
Infra welcomes government efforts, stocks surge: UR Asso
Outlook on infrastructure sector: UR Associates
New pricing policy to impact pharma cos in short term
Infra targets need to be met for resurgence in growth
FIPB approved 8 FDI brownfield proposals in pharma sector
Infra firms fail to attract investment: UR Associates
Pharmaceutical sector roundup: UR Associates
Agriculture sector roundup: UR Associates
GVK Power to sell stake in Australian rail, port arms
Glenmark wins case against Napo Pharma
Coarse cereals, pulses sowing still lagging behind normal
Pharma industry seen at $60bn by end of 12th plan
Infra: Environmental clearances a major hurdle for progress
Better rainfall cuts monsoon deficiency to 15% below normal
Agri roundup: How the drought is likely to pan out
Infra round up: The good, the bad and the ugly
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio